Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Update on Repligen's angiogenesis inhibitors

May 1, 1998

CyDex and Allergan sign option for ophthalmic drug delivery technology

April 29, 1998

New antiglaucoma agent approved in U.S.

April 24, 1998

Another European launch for Alphagan

April 23, 1998

Akorn acquires ophthalmic products from Alza

April 20, 1998

Cosopt receives marketing approval from FDA

April 16, 1998

Bio-Technology General signs U.S. marketing agreement with Akorn for BioLon

April 15, 1998

New ocular agents described by Novartis

March 30, 1998

QLT and Ciba Vision initiate phase IIIb verteporfin trial

March 20, 1998

FDA approves ocular antiinflammatory agent

March 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.